Cinven formed AMCo through the merger of two business, Mercury Pharma (acquired in August 2012) and Amdipharm (acquired in October 2012). AMCo was a specialty pharmaceutical company focused on the sale of niche, prescription off-patent products. The company marketed its products in c. 100 countries across the globe with a primary focus on the U.K. and European markets. AMCo had significant operational bases in the U.K. and India, with a direct sales presence in the U.K., Ireland, the Netherlands and the Nordic region, and made its international sales through distributors.
In October 2015 Cinven completed the successful sale of AMCo to Concordia International Corporation, a Canada-headquartered, TSX / Nasdaq-listed diverse healthcare company, focused on legacy pharmaceutical products and orphan drugs. As part of the consideration Cinven received shares in Concordia, which Cinven continues to hold.